IMVT
HealthcareImmunovant, Inc. · Biotechnology · $7B
What is Immunovant, Inc.?
Immunovant is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Incorporated in 2018 and headquartered in New York City, it operates as a subsidiary of Roivant Sciences Ltd.
Immunovant's core work centers on developing monoclonal antibodies that target the immune system's underlying mechanisms in autoimmune conditions. Its lead candidate, batoclimab, is a fully human monoclonal antibody designed to inhibit the neonatal Fc receptor — a pathway that regulates certain disease-driving antibodies. The company has advanced batoclimab into multiple clinical trials across conditions including myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia. Revenue generation depends entirely on future clinical and regulatory success.
Immunovant was incorporated in 2018 and is headquartered in New York City, New York.
- Batoclimab — neonatal Fc receptor inhibitor in clinical development
- Phase II trials across multiple autoimmune indications
- Myasthenia gravis and thyroid eye disease programs
- Warm autoimmune hemolytic anemia clinical program
Is IMVT a Good Stock to Buy?
UQS Score rates IMVT as Poor overall, reflecting the early-stage nature of the business and the uncertainties inherent in clinical-stage drug development.
Among the five pillars, Risk comes in at a Neutral rating — suggesting that while the company carries meaningful uncertainty, its risk profile is not at the extreme end relative to other clinical-stage peers. This is partly attributable to its backing from Roivant Sciences.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue company that has no established commercial product, no durable competitive advantage yet, and no near-term earnings base. Valuation is rated Elevated, meaning the current market price already reflects significant optimism about pipeline outcomes.
Pro members can view the full pillar breakdown and detailed financial metrics behind IMVT's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does IMVT pay dividends?
No — Immunovant, Inc. does not currently pay a dividend.
Immunovant does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding research, clinical trials, and pipeline advancement. Investors in IMVT are generally seeking potential long-term value from drug approvals rather than current income.
When does IMVT report earnings?
Immunovant reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, Immunovant's quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to move the stock more than earnings figures.
For the most recent quarter's results and pipeline updates, visit Immunovant's investor relations page directly.
IMVT Price History
+86.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Immunovant, Inc.?
Based on Immunovant, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
IMVT Long-term Outlook
Immunovant's fundamental outlook is shaped almost entirely by the clinical trajectory of batoclimab. With Growth and Quality both rated Weak, the company has no near-term commercial revenue base to fall back on. A Neutral Risk rating suggests the balance sheet and operational structure are not in immediate distress, but the Elevated Valuation label indicates the market has already priced in meaningful pipeline success — leaving limited margin for setbacks.
Growth drivers
- Positive Phase II readouts across multiple autoimmune indications
- Potential regulatory advancement of batoclimab toward pivotal trials
- Roivant Sciences' operational and financial backing
Key risks
- Clinical trial failure or disappointing efficacy data
- Elevated valuation leaves little room for pipeline delays
- Dependence on external funding with no commercial revenue
IMVT vs Peers
Immunovant operates in a competitive clinical-stage landscape alongside other specialty biopharmaceutical companies pursuing differentiated therapeutic approaches.
Caris focuses on molecular profiling and precision oncology diagnostics, operating in a different segment of the healthcare value chain than Immunovant's antibody-based autoimmune approach.
PTC Therapeutics targets rare genetic disorders with an approved commercial product portfolio, giving it a more established revenue base compared to Immunovant's pre-commercial stage.
Celcuity is a clinical-stage oncology company developing targeted therapies, sharing the pre-revenue risk profile of Immunovant but pursuing a distinct disease area and mechanism.
Frequently Asked Questions
What does Immunovant do?
Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibodies for autoimmune diseases. Its lead program, batoclimab, targets the neonatal Fc receptor — a mechanism involved in driving certain autoimmune conditions. The company is currently running multiple Phase II clinical trials across indications including myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia.
Does IMVT pay dividends?
No, Immunovant does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and clinical development. Investors in IMVT are generally focused on the potential long-term value of a successful drug approval rather than current income.
When does IMVT report earnings?
Immunovant reports on a quarterly cadence, as is standard for US-listed public companies. Because it is pre-revenue, pipeline updates and clinical trial milestones are often more market-moving than the financial figures themselves. Check Immunovant's investor relations page for the latest scheduled reporting dates.
Is IMVT a good stock to buy?
UQS Score rates IMVT as Poor, driven by Weak ratings across Quality, Moat, and Growth pillars — all consistent with a pre-commercial company. The Elevated Valuation rating suggests the market has already priced in significant pipeline optimism. Investors should weigh clinical-stage risk carefully. The full pillar breakdown is available to Pro members on uqs-score.com.
Is IMVT overvalued?
UQS Score's Valuation pillar for IMVT is rated Elevated, meaning the current market price appears to reflect considerable expectations about future pipeline success. For a company with no commercial revenue, this leaves limited buffer if clinical results disappoint. The detailed valuation metrics behind this rating are available in the full Pro analysis.
How does IMVT compare to its competitors?
Compared to peers like PTC Therapeutics, which has an established commercial product base, Immunovant is at an earlier stage with no approved products. Relative to other clinical-stage companies like Celcuity, Immunovant is differentiated by its focus on autoimmune disease and its neonatal Fc receptor mechanism. Full peer comparisons are available on uqs-score.com.
What is IMVT's market cap bracket?
Immunovant is classified as a mid-cap company. This places it in a range that typically attracts both institutional and retail investor attention, though for a clinical-stage biotech, market cap can be highly sensitive to trial outcomes and pipeline news.
Who founded Immunovant?
Immunovant was incorporated in 2018 and operates as a subsidiary of Roivant Sciences Ltd. Founding and leadership details are publicly available through the company's official filings and investor relations materials.
Is IMVT a long-term quality investment?
As a long-term quality indicator, UQS Score rates IMVT as Poor. The Weak ratings across Quality, Moat, and Growth pillars reflect the absence of durable competitive advantages and an established earnings base. Long-term quality typically requires demonstrated profitability and a defensible market position — neither of which Immunovant has established yet.
What is the main competitive advantage of Immunovant?
Immunovant's potential advantage lies in its neonatal Fc receptor inhibition approach, which targets a mechanism relevant across multiple autoimmune diseases. If batoclimab demonstrates strong efficacy across indications, it could address a broad patient population. However, UQS Score currently rates Immunovant's Moat as Weak, reflecting the pre-commercial stage of this advantage.
What sector does IMVT belong to?
Immunovant operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. This segment is characterized by high research costs, binary clinical outcomes, and long development timelines before any commercial revenue is generated. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) on uqs-score.com.
Is IMVT a growth stock or value stock?
Based on UQS pillar labels, IMVT does not fit neatly into either category. Its Growth pillar is rated Weak — reflecting no current revenue growth — while its Valuation is rated Elevated, ruling out a traditional value framing. It is best understood as a clinical-stage speculative holding rather than a conventional growth or value stock.
Unlock Full IMVT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare IMVT against scored healthcare peers
- ✓Track pipeline risk through the Risk pillar detail
- ✓See valuation context versus clinical-stage benchmarks
- ✓Get the full analyst view reserved for Pro members
Pro Analysis
IMVT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 11.6 | 0.0 | 11.0 | 2.6 | 55.8 | 0.0 | +1.9 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -1.4 |
| Apr 2, 2026 | 11.1 | 0.0 | 11.0 | 0.0 | 55.8 | 0.0 | — |
IMVT — Pillar Breakdown
Quality
— 0.0/100 (25%)Immunovant, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 2.6/100 (20%)Immunovant, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 59.2/100 (15%)Immunovant, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Immunovant, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Immunovant, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IMVT.
Score Composition
Financial Data
More Stock Analysis
How is the IMVT UQS Score Calculated?
The UQS (Unified Quality Score) for Immunovant, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Immunovant, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Immunovant, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.